Singular Genomics Systems, Inc.
singulargenomics.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2024 10-Q, filed Nov 12, 2024. Its latest SEC filing is a SCHEDULE 13G/A from May 15, 2025.
10-Q for Q3 FY2024, filed Nov 12, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Develops and sells genomic sequencing instruments and consumables, and is developing spatial analysis tools for researchers, laboratories, and biotechnology and biopharmaceutical companies.
10-K for FY2023, filed Mar 18, 2024We are a life science technology company that develops next-generation sequencing and spatial multiomics technologies. The commercially…View ↗
Our active product development pipeline is comprised of two products, each of which is designed to leverage the Sequencing Engine and…View ↗
We plan to initially sell and market our products for research use only (“RUO”) to academic institutions, life sciences and research…View ↗
How Did They Make Money?
Customers pay for G4 instruments when they accept them and for consumable kits when they are shipped. They are invoiced for services in advance, with service revenue spread across the service period.
10-K for FY2023, filed Mar 18, 2024
$2.9M
-
10-K for FY2023, filed Mar 18, 2024
$2.9M ↗
Who Were Their Customers?
The company plans to sell research-use products to academic institutions, life sciences and research laboratories, and biopharmaceutical and biotechnology companies. It sells the G4 through a direct sales organization in the United States, with future sales planned through direct channels or distribution networks in other regions.
10-K for FY2023, filed Mar 18, 2024
Did Revenues Turn Into Profits?
No. It lost $94.8M in FY2023.
10-K for FY2023, filed Mar 18, 2024
−$102.8MView ↗
10-K for FY2023, filed Mar 18, 2024
−$94.8MView ↗
10-K for FY2023, filed Mar 18, 2024
−$74.6MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2024, filed Nov 12, 2024
−$16.8MView ↗
- ▼ −25% (Loss)
- vs −$22.4M in Q3 FY2023
-
Feb 27, 2025
Deerfield completed its acquisition and Singular Genomics became private
Josh Stahl became CEO, and Drew Spaventa left the CEO role.
Sources
8-K, filed Feb 27, 2025
Following the satisfaction of customary conditions, including a vote of the holders of Singular Genomics’ common stock to approve the…View ↗
-
Dec 23, 2024
Singular Genomics agreed to be acquired by Deerfield for cash
The agreement provided $20.00 per share in cash for eligible shares.
Sources
8-K, filed Dec 23, 2024
Under the terms of the Merger Agreement and subject to the conditions set forth therein, at the Effective Time of the Merger, each share of…View ↗
Who Did They Compete With?
Competes with 10x Genomics, Becton, Dickinson and, Bio-Rad Laboratories, Illumina, MissionBio, Nanostring Technologies, Oxford Nanopore Technologies, Pacific Biosciences, Element Biosciences, Ultima Genomics, and Thermo Fisher Scientific
10-K for FY2023, filed Mar 18, 2024The life sciences market is highly competitive. There are other companies, both established and early-stage, that have indicated that they…View ↗
Loading...
